PT - JOURNAL ARTICLE AU - Bonde, Jesper AU - Ejegod, Ditte AU - Pedersen, Helle AU - Smith, Birgitte AU - Cortes, Dina AU - Leding, Cæcilie AU - Thomsen, Thorbjørn AU - Benfield, Thomas AU - Schnieder, Uffe Vest AU - Tingleff, Jens AU - Arbyn, Marc AU - Lisby, Gorm AU - Andersen, Ove TI - Clinical validation of point-of-care SARS-COV-2 BD Veritor antigen test by a single throat swab for rapid COVID-19 status on hospital patients predominantly without overt COVID symptoms AID - 10.1101/2021.04.12.21255299 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.12.21255299 4099 - http://medrxiv.org/content/early/2021/04/17/2021.04.12.21255299.short 4100 - http://medrxiv.org/content/early/2021/04/17/2021.04.12.21255299.full AB - BACKGROUND Fast identification of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) infected individuals is a strategically vital task to ensure correct management and quarantine. Rapid antigen test could be a supplement to the standard-of-care Nucleic Acid Amplification Test (NAAT). The aim of this study was to determine the accuracy of the BD Veritor SARS-CoV-2 antigen test as a screening instrument in a hospital setting.METHODS A cohort of prospective samples were collected from hospital staff and patients at the Emergency, Infectious Diseases and Pediatrics and Adolescent Medicine departments at Hvidovre Hospital. All samples were collected using oropharyngeal swabs, and BD Veritor Antigen test results were paired with routine NAAT test results. Sensitivity, specificity, positive and negative predictive values of the antigen test were calculated using NAAT as reference.RESULTS Overall, 809 samples from 674 individuals were included (average age 45 years, range 0-98 years). Among all samples, 8% were SARS-CoV-2 positive by NAAT testing and 5.3% by BD Veritor. The sensitivity of the antigen test was 63.1% and specificity 99.7%. The positive predictive value was 95.3%. False-positive rate was 4%. The cycle threshold value was significantly higher among individuals with false negative antigen tests compared to true positives.CONCLUSION The sensitivity, specificity and positive predictive values show that the BD Veritor antigen test from oropharyngeal collected specimens performs well. Antigen testing may be a supplement, but not substitute, to NAAT testing as the primary diagnostic modality in hospital settings where fast turnaround test results may assist in decisions regarding isolation and quarantine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialStudy was registered as a quality development studyFunding StatementSample collection, testing and project management was embedded into the routine of the participating departments. BD Diagnostics, Sparks, MD, donated BD Veritor SARS-CoV-2 antigen tests and Veritor analyzers free-of-charge. The donor had no role in data handling, data presentation, or resulting publication. Marc Arbyn was supported by the Validation of Coronavirus Assays (VALCOR) project (Sciensano, Brussels, Begium).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Capital Region of Denmark, records H-20080005 and H-20028292All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available for external review upon request if provided with relevant Danish Data Protection Agency approvals in concordance with current Danish Law.